Chemistry:Lys-MDA

From HandWiki

Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[1][2][3][4] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.[5] The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.[6]

See also

References

  1. "MindMed announces Phase 1 study of MDMA-like substances.". Drug Discovery and Development. 21 September 2022. https://www.drugdiscoverytrends.com/mindmed-announces-phase-1-study-of-mdma-like-substances/. 
  2. "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances.". Biospace.com. 20 September 2022. https://www.biospace.com/article/releases/mindmed-collaborators-dose-first-patient-in-phase-1-investigator-initiated-trial-of-mdma-like-substances/. 
  3. Grill M, "Novel Safrylamine derivatives having prodrug properties.", WO patent 2022/053696, published 17 March 2022, assigned to Compass Pathfinder Limited.
  4. Clark S, Duncton MA, "Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof", WO patent 2023/283373, published 12 January 2023, assigned to Terran Biosciences Inc.
  5. ClinicalTrials.gov. 13 August 2024. https://clinicaltrials.gov/study/NCT04847206. Retrieved 13 November 2024. 
  6. "Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants". Neuropsychopharmacology. September 2025. doi:10.1038/s41386-025-02248-3. PMID 40999236. 

Template:Psychedelics